Researchers explored whether a direct-to-patient digital intervention could increase the number of lung cancer screening CTs among patients in 2 US health systems.

There was no significant difference in survival outcomes for patients with advanced neuroendocrine tumors who were treated with low-dose everolimus compared to standard-dose everolimus, according to a ...

HealthDay News — Multicancer early detection (MCED) tests can increase earlier-stage diagnoses and reduce late-stage diagnoses, according to a study published online Nov. 10 in Cancer.

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

The researchers found that the risk for depression was higher among breast cancer survivors than controls (hazard ratio, 5.94). Insomnia (defined as ≥8 on the Insomnia Severity Index) further ...

Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an ...

The treatment effects on PFS were consistent regardless of modeling approach and for both targeted and nontargeted therapies.

Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and ...

Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested the anti-PDL-1 antibody avelumab in patients with locally advanced or metastatic penile cancer ...